What is EvolveImmune Therapeutics?
EvolveImmune Therapeutics is a biotechnology firm dedicated to overcoming the limitations of current cancer immunotherapies. The company specializes in the development of unique trispecific T cell engagers that incorporate integrated CD2 costimulation. This innovative approach is designed to counteract the mechanisms of cancer cell resistance that often render traditional therapies ineffective. The company's lead candidate, EVOLVE104, represents a significant advancement in the field, with clinical trials slated for 2025. Beyond its internal pipeline, EvolveImmune has established a high-profile partnership with AbbVie, further validating its scientific methodology and expanding its potential to address unmet medical needs in oncology.
How much funding has EvolveImmune Therapeutics raised?
EvolveImmune Therapeutics has raised a total of $37M across 1 funding round:
Other Financing Round
$37M
Other Financing Round (2023): $37M with participation from Pfizer and Bristol-Myers Squibb
Key Investors in EvolveImmune Therapeutics
Pfizer
Pfizer is a global biopharmaceutical leader that researches, develops, and manufactures vaccines and medicines across diverse therapeutic areas, with a strong emphasis on oncology and immunology.
Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical organization focused on discovering and developing innovative medications for serious diseases, including a robust portfolio in oncology and immunoscience.
What's next for EvolveImmune Therapeutics?
Looking ahead, the primary objective for EvolveImmune Therapeutics is the successful initiation of clinical trials for EVOLVE104 in 2025. The recent capital infusion provides the necessary runway to scale manufacturing processes and expand the research team. Furthermore, the strategic alliance with AbbVie serves as a force multiplier, allowing the company to leverage external expertise while maintaining its focus on its core trispecific platform. As the company moves toward human trials, the focus will shift toward demonstrating safety and efficacy, which will be critical for future valuation and potential long-term commercialization strategies in the competitive immunotherapy market.
See full EvolveImmune Therapeutics company page
